KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Change in Cash: 2009-2025

Historic Change in Cash for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $41.0 million.

  • Ionis Pharmaceuticals' Change in Cash rose 1.05% to $41.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 121.40%. This contributed to the annual value of -$157.2 million for FY2024, which is 228.01% down from last year.
  • Ionis Pharmaceuticals' Change in Cash amounted to $41.0 million in Q3 2025, which was up 23.93% from $33.1 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Change in Cash ranged from a high of $236.2 million in Q4 2021 and a low of -$326.7 million during Q1 2022.
  • Its 3-year average for Change in Cash is $5.6 million, with a median of $32.6 million in 2023.
  • Its Change in Cash has fluctuated over the past 5 years, first crashed by 2,080.95% in 2022, then soared by 662.05% in 2023.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Change in Cash stood at $236.2 million in 2021, then slumped by 116.31% to -$38.5 million in 2022, then soared by 222.55% to $47.2 million in 2023, then slumped by 296.01% to -$92.5 million in 2024, then rose by 1.05% to $41.0 million in 2025.
  • Its last three reported values are $41.0 million in Q3 2025, $33.1 million for Q2 2025, and $22.1 million during Q1 2025.